The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

The company is set to become the first $1tn drugmaker, but investors see warning signs it has reached ‘peak enthusiasm’ ...

First, let's take a quick look at why Lilly's drugs and others of the same class are so popular. Mounjaro and Zepbound are ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ... to the company for comment. Eli Lilly, the manufacturer of ...

England’s National Health Service (NHS) on Thursday proposed to launch Eli Lilly's (NYSE ... also known as Zepbound, will be offered to patients with a BMI of more than 40 kg/m2.

Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.S. Food and Drug Administration (FDA) that competitor Eli Lilly ... and Zepbound, have been popular ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...

Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ...

GLP-1 drugs, which mimic hormones that regulate blood sugar and suppress appetite, have become highly sought after for ... while Zepbound was added this April. Eli Lilly did not immediately ...